https://orcid.org/0000-0003-1803-2046
Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Luca Potestio, Angelo Ruggiero, Gabriella Fabbrocini, Fabrizio Martora & Matteo Megna. (2023) Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature. Psoriasis: Targets and Therapy 13, pages 19-26.
Read now
Read now
Luca Potestio, Fabrizio Martora, Gabriella Fabbrocini, Teresa Battista & Matteo Megna. (2023) Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis. Psoriasis: Targets and Therapy 13, pages 11-18.
Read now
Read now
Sara Cacciapuoti, Luca Potestio, Gianluca Guerrasio, Gabriella Fabbrocini, Massimiliano Scalvenzi, Angelo Ruggiero, Giuseppina Caiazzo & Matteo Megna. (2023) Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas. Clinical, Cosmetic and Investigational Dermatology 16, pages 2637-2644.
Read now
Read now
Teresa Battista, Massimiliano Scalvenzi, Fabrizio Martora, Luca Potestio & Matteo Megna. (2023) Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments. Clinical, Cosmetic and Investigational Dermatology 16, pages 1899-1932.
Read now
Read now
Luca Potestio, Elisa Camela, Sara Cacciapuoti, Luigi Fornaro, Angelo Ruggiero, Fabrizio Martora, Teresa Battista & Matteo Megna. (2023) Biologics for the Management of Erythrodermic Psoriasis: An Updated Review. Clinical, Cosmetic and Investigational Dermatology 16, pages 2045-2059.
Read now
Read now
Matteo Megna, Elisa Camela, Angelo Ruggiero, Teresa Battista, Fabrizio Martora, Sara Cacciapuoti & Luca Potestio. (2023) Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?. Clinical, Cosmetic and Investigational Dermatology 16, pages 1677-1690.
Read now
Read now
Luca Potestio, Ilaria Piscitelli, Gabriella Fabbrocini, Fabrizio Martora, Angelo Ruggiero & Matteo Megna. (2023) Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection. Clinical, Cosmetic and Investigational Dermatology 16, pages 369-373.
Read now
Read now
Fabrizio Martora, Matteo Megna, Teresa Battista, Luca Potestio, Maria Carmela Annunziata, Claudio Marasca, Alessia Villani & Gabriella Fabbrocini. (2023) Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience. Clinical, Cosmetic and Investigational Dermatology 16, pages 135-148.
Read now
Read now
Luca Potestio, Elisa Camela, Sara Cacciapuoti, Fabrizio Martora, Luigi Guerriero, Luigi Fornaro, Angelo Ruggiero & Matteo Megna. (2023) Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation. Expert Opinion on Drug Safety 22:11, pages 1003-1010.
Read now
Read now
Elisa Camela, Luca Potestio, Gabriella Fabbrocini, Sabatino Pallotta & Matteo Megna. (2023) The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opinion on Investigational Drugs 32:6, pages 537-552.
Read now
Read now
Jonathan K. Hwang & Shari R. Lipner. (2023) Safety of current systemic therapies for nail psoriasis. Expert Opinion on Drug Safety 22:5, pages 391-406.
Read now
Read now
Angelo Ruggiero, Luca Potestio, Fabrizio Martora, Alessia Villani, Rosita Comune & Matteo Megna. (2023) Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert Opinion on Drug Safety 22:5, pages 355-362.
Read now
Read now
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Angelo Ruggiero, Giuseppe Monfrecola, Gabriella Fabbrocini & Luca Potestio. (2023) Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opinion on Drug Safety 22:1, pages 43-58.
Read now
Read now
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Angelo Ruggiero, Giuseppe Monfrecola, Gabriella Fabbrocini & Luca Potestio. (2023) Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opinion on Drug Safety 22:1, pages 25-41.
Read now
Read now
Elisa Camela, Luca Potestio, Angelo Ruggiero, Sonia Sofia Ocampo-Garza, Gabriella Fabbrocini & Matteo Megna. (2022) Towards Personalized Medicine in Psoriasis: Current Progress. Psoriasis: Targets and Therapy 12, pages 231-250.
Read now
Read now
Fabrizio Martora, Teresa Battista, Claudio Marasca, Lucia Genco, Gabriella Fabbrocini & Luca Potestio. (2022) Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature. Clinical, Cosmetic and Investigational Dermatology 15, pages 2369-2382.
Read now
Read now
Angelo Ruggiero, Fabrizio Martora, Gabriella Fabbrocini, Alessia Villani, Claudio Marasca, Matteo Megna, Luigi Fornaro, Rosita Comune & Luca Potestio. (2022) The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review. Clinical, Cosmetic and Investigational Dermatology 15, pages 2785-2793.
Read now
Read now
Angelo Ruggiero, Elisa Camela, Luca Potestio, Gabriella Fabbrocini & Matteo Megna. (2022) Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opinion on Drug Safety 21:12, pages 1445-1451.
Read now
Read now
Sunil Dogra & Hitaishi Mehta. (2022) Biological treatment for erythrodermic psoriasis. Expert Opinion on Biological Therapy 22:12, pages 1531-1543.
Read now
Read now
Articles from other publishers (5)
Fabrizio Martora, Gabriella Fabbrocini, Matteo Megna, Massimiliano Scalvenzi, Teresa Battista, Alessia Villani & Luca Potestio. (2023) Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future?. Life 13:4, pages 1037.
Crossref
Crossref
Elena Campione, Sara Lambiase, Ruslana Gaeta Shumak, Marco Galluzzo, Caterina Lanna, Gaetana Costanza, Cristiana Borselli, Fabio Artosi, Terenzio Cosio, Lorenzo Tofani, Annunziata Dattola, Francesca Di Daniele & Luca Bianchi. (2023) A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients. Pharmaceuticals 16:4, pages 526.
Crossref
Crossref
Shan Huang & Yanping Bai. (2023) Knowledge Mapping and Research Hotspots of Comorbidities in Psoriasis: A Bibliometric Analysis from 2004 to 2022. Medicina 59:2, pages 393.
Crossref
Crossref
Huanan Yu, Yuanqi Liu, Fang Zheng, Wenyu Chen & Kun Wei. (2022) Erianin-Loaded Photo-Responsive Dendrimer Mesoporous Silica Nanoparticles: Exploration of a Psoriasis Treatment Method. Molecules 27:19, pages 6328.
Crossref
Crossref
Yun Zhou, Lixian Zhong, Lianli Shen, Sisi Chen, Qiuting Zeng, Leizhen Lai & Shaohui Tang. (2022) Psoriasis and medical ramifications: A comprehensive analysis based on observational meta-analyses. Frontiers in Medicine 9.
Crossref
Crossref